Kezar Life Sciences (NASDAQ:KZR - Get Free Report)'s stock had its "buy" rating restated by analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They currently have a $20.00 price target on the stock.
Kezar Life Sciences Stock Performance
Shares of KZR stock traded down $0.04 during trading hours on Friday, hitting $0.77. The stock had a trading volume of 1,066,209 shares, compared to its average volume of 684,672. The firm has a market capitalization of $56.25 million, a PE ratio of -0.58 and a beta of 0.47. Kezar Life Sciences has a twelve month low of $0.67 and a twelve month high of $3.13. The stock's 50 day moving average is $0.87 and its 200 day moving average is $0.87. The company has a debt-to-equity ratio of 0.05, a current ratio of 11.66 and a quick ratio of 11.66.
Kezar Life Sciences (NASDAQ:KZR - Get Free Report) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.04. As a group, research analysts forecast that Kezar Life Sciences will post -1.26 earnings per share for the current fiscal year.
Institutional Trading of Kezar Life Sciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in KZR. SG Americas Securities LLC lifted its stake in shares of Kezar Life Sciences by 33.8% in the 4th quarter. SG Americas Securities LLC now owns 43,950 shares of the company's stock valued at $42,000 after purchasing an additional 11,109 shares in the last quarter. Fidelis Capital Partners LLC acquired a new position in shares of Kezar Life Sciences in the 1st quarter valued at about $25,000. Pale Fire Capital SE acquired a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $82,000. BNP Paribas Financial Markets lifted its stake in shares of Kezar Life Sciences by 35.4% in the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company's stock valued at $247,000 after purchasing an additional 71,543 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in shares of Kezar Life Sciences in the 4th quarter valued at about $80,000. Hedge funds and other institutional investors own 67.90% of the company's stock.
About Kezar Life Sciences
(
Get Free Report)
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
Featured Articles
Before you consider Kezar Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kezar Life Sciences wasn't on the list.
While Kezar Life Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
